Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer

Conversely, anthracycline-free regimens were used more frequently in low-risk cases (78.9%) than in high-risk ones (45.5%), although this trend did not reach statistical significance ( p = 0.16).

also in 111,027 other papers

This effect was driven by the complementary contribution of its components: the pCR score supported de-escalation in tumors with high probability of response, while the Risk score showed a trend toward further stratifying treatment intensity, with a ≈30% greater use of anthracycline-free regimens in low-risk tumors and anthracyclines administered exclusively in the high-risk subgroup, with the ERBB2 score providing additional support for anthracycline-sparing strategies.

also in 53,322 other papers